Establishment of a yeast-based VLP platform for antigen presentation
White Paper | ARTES Biotechnology GmbH
Background: Chimeric virus‑like particles (VLP) allow the display of foreign antigens on their surface and have proved valuable in the development of safe subunit vaccines or drug delivery. However, finding an inexpensive production system and a VLP scaffold that allows stable incorporation of diverse, large foreign antigens are major challenges in this field.
Results: In this study, a versatile and cost‑effective platform for chimeric VLP development was established. The membrane integral small surface protein (dS) of the duck hepatitis B virus was chosen as VLP scaffold and the industri‑ally applied and safe yeast Hansenula polymorpha (syn. Pichia angusta, Ogataea polymorpha) as the heterologous expression host. Eight different, large molecular weight antigens of up to 412 amino acids derived from four animal‑infecting viruses were genetically fused to the dS and recombinant production strains were isolated. In all cases, the fusion protein was well expressed and upon co‑production with dS, chimeric VLP containing both proteins could be generated. Purification was accomplished by a downstream process adapted from the production of a recombinant hepatitis B VLP vaccine. Chimeric VLP were up to 95% pure on protein level and contained up to 33% fusion protein. Immunological data supported surface exposure of the foreign antigens on the native VLP. Approximately 40 mg of chimeric VLP per 100 g dry cell weight could be isolated. This is highly comparable to values reported for the opti‑mized production of human hepatitis B VLP. Purified chimeric VLP were shown to be essentially stable for 6 months at 4 °C.
Conclusions: The dS‑based VLP scaffold tolerates the incorporation of a variety of large molecular weight foreign protein sequences. It is applicable for the display of highly immunogenic antigens originating from a variety of pathogens. The yeast‑based production system allows cost‑effective production that is not limited to small‑scale fundamental research. Thus, the dS‑based VLP platform is highly efficient for antigen presentation and should be considered in the development of future vaccines.
David Wetzel, Theresa Rolf, Manfred Suckow, Andreas Kranz, Andreas Barbian, Jo‑Anne Chan, Joachim Leitsch, Michael Weniger, Volker Jenzelewski, Betty Kouskousis, Catherine Palmer, James G. Beeson, Gerhard Schembecker, Juliane Merz and Michael Piontek.
This paper is published under the Creative Commons Licence.
To learn more about Establishment of a yeast-based VLP platform for antigen presentation, please click on the White Paper below:
Click on Establishment of a yeast-based VLP platform for antigen presentation for more information.
Click on ARTES to contact the company directly.
Click on Microbial Cell Factories to access the online paper.
Click on Establishment of a yeast-based VLP platform to access the source.
Click on BioMed Central to learn more about the publisher.
Supplier: ARTES Biotechnology GmbH
Address: Elisabeth-Selbert-Str. 9, 40764 Langenfeld, Germany
Tel: +49 (0) 2173 27587-0
Fax: +49 (0) 2173 27587-77